Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-c01e0605e2e3c43213448cfeba0686aa"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-c01e0605e2e3c43213448cfeba0686aa"/>
<resource>
<Composition>
<id value="composition-en-c01e0605e2e3c43213448cfeba0686aa"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-c01e0605e2e3c43213448cfeba0686aa"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-c01e0605e2e3c43213448cfeba0686aa</b></p><a name="composition-en-c01e0605e2e3c43213448cfeba0686aa"> </a><a name="hccomposition-en-c01e0605e2e3c43213448cfeba0686aa"> </a><a name="composition-en-c01e0605e2e3c43213448cfeba0686aa-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1625/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - paxlovid</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1625/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpc01e0605e2e3c43213448cfeba0686aa"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - paxlovid"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Paxlovid is and what it is used for</li><li>What you need to know before you take Paxlovid</li><li>How to take Paxlovid</li><li>Possible side effects</li><li>How to store Paxlovid</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What paxlovid is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What paxlovid is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Paxlovid contains two active substances nirmatrelvir and ritonavir in two different tablets. Paxlovid is an antiviral medicine used for treating adults with COVID-19 who do not require supplemental oxygen and who are at increased risk for progressing to severe disease.</p><p>COVID-19 is caused by a virus called a coronavirus. Paxlovid stops the virus multiplying in cells and this stops the virus multiplying in the body. This can help your body to overcome the virus infection, and may prevent you from developing severe illness.</p><p>If your symptoms worsen or do not improve after 5 days, talk to your doctor.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take paxlovid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take paxlovid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Paxlovid</p><ul><li><p>if you are allergic to nirmatrelvir, ritonavir or any of the other ingredients of Paxlovid (listed in section 6).</p></li><li><p>if you are taking any of the following medicines. Taking Paxlovid with these medicines may cause serious or life-threatening side effects or affect how Paxlovid works:</p></li><li><p>Alfuzosin (used to treat symptoms of an enlarged prostate)</p></li><li><p>Ranolazine (used to treat chronic chest pain [angina])</p></li><li><p>Dronedarone, propafenone, quinidine (used to treat heart conditions and correct irregular heartbeats)</p></li><li><p>Rifampicin, rifapentine (used to treat bacterial infections)</p></li><li><p>Apalutamide, neratinib, venetoclax (used to treat cancer)</p></li><li><p>Carbamazepine, phenobarbital, phenytoin, primidone (used to prevent and control seizures)</p></li><li><p>Colchicine (used to treat gout)</p></li><li><p>Terfenadine (used to treat allergies)</p></li><li><p>Lurasidone (used to treat schizophrenia)</p></li><li><p>Pimozide, quetiapine (used to treat schizophrenia, bipolar disorder, severe depression and abnormal thoughts or feelings)</p></li><li><p>Silodosin (used to treat enlarged prostate gland)</p></li><li><p>Eplerenone and ivabradine (used to treat heart and/or blood vessel problems)</p></li><li><p>Dihydroergotamine and ergotamine (used to treat migraine headaches)</p></li><li><p>Ergonovine and methylergonovine (used to stop excessive bleeding that may occur following childbirth or an abortion)</p></li><li><p>Cisapride (used to relieve certain stomach problems)</p></li><li><p>St. John s wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety)</p></li><li><p>Voclosporin (used to treat immune disorders)</p></li><li><p>Lovastatin, simvastatin, lomitapide (used to lower blood cholesterol)</p></li><li><p>Eletriptan (used to treat migraine headaches)</p></li><li><p>Lumacaftor/ivacaftor (used for cystic fibrosis)</p></li><li><p>Finerenone (used to treat chronic kidney disease associated with Type 2 diabetes)</p></li><li><p>Naloxegol (used to treat opioid-induced constipation)</p></li><li><p>Avanafil, vardenafil (used to treat erectile dysfunction [also known as impotence])</p></li><li><p>Sildenafil, tadalafil (used to treat erectile dysfunction [also known as impotence] or pulmonary arterial hypertension [high blood pressure in the pulmonary artery])</p></li><li><p>Clorazepate, diazepam, estazolam, flurazepam, triazolam, midazolam taken orally (used to relieve anxiety and/or trouble sleeping)</p></li><li><p>Tolvaptan used to treat hyponatremia (low sodium levels in the blood)</p></li></ul><p>Warnings and precautions</p><p>Allergic reactions Allergic reactions, including severe allergic reactions (known as anaphylaxis ) and serious skin reactions (known as toxic epidermal necrolysis and Stevens-Johnson syndrome ), can happen in people taking Paxlovid, even after only 1 dose. Stop taking Paxlovid and call your doctor right away if you get any of the following symptoms of an allergic reaction:</p><ul><li>trouble swallowing or breathing</li><li>swelling of the tongue, mouth, and face</li><li>throat tightness</li><li>hoarseness</li><li>itching</li><li>skin rash</li><li>red and painful skin</li><li>blisters and peeling skin</li><li>blisters or sores in your mouth or lips</li></ul><p>Liver disease Tell your doctor if you have or have had a liver disease. Liver enzyme abnormalities, hepatitis and jaundice have occurred in patients receiving ritonavir.</p><p>Kidney disease Tell your doctor if you have or have had a kidney disease.</p><p>High blood pressure Tell your doctor if you have high blood pressure. Your doctor may need to check your blood pressure before taking Paxlovid and while you are taking this medicine. There have been reports of high blood pressure in people taking Paxlovid, particularly in older individuals.</p><p>Risk of HIV-1 resistance development If you have untreated or uncontrolled HIV infection, Paxlovid may lead to some HIV medicines not working as well in the future. Children and adolescents Do not give Paxlovid to children and adolescents under 18 years because Paxlovid has not been studied in children and adolescents.</p><p>Other medicines and Paxlovid There are other medicines that may not be taken together with Paxlovid. Tell your doctor(s) or pharmacist if you are taking, have recently taken or might take any other medicines:</p><ul><li><p>medicines used to treat cancer, such as afatinib, abemaciclib, ceritinib, dasatinib, encorafenib, fostamatinib, ibrutinib, ivosidenib, nilotinib, vinblastine and vincristine</p></li><li><p>medicines used to thin the blood (anticoagulants), such as warfarin, rivaroxaban, dabigatran and apixaban</p></li><li><p>medicines used to treat convulsions, such as divalproex, lamotrigine and clonazepam</p></li><li><p>medicines used for smoking cessation, such as bupropion</p></li><li><p>medicines used to treat allergies, such as fexofenadine and loratadine</p></li><li><p>medicines used to treat fungal infections (antifungals), such as itraconazole and voriconazole</p></li><li><p>medicines used to treat Cushing s syndrome when the body produces an excess of cortisol such as ketoconazole tablets</p></li><li><p>medicines used to treat HIV infection, such as efavirenz, maraviroc, raltegravir, zidovudine and bictegravir/emtricitabine/tenofovir</p></li><li><p>medicines used to treat infections (e.g., antibiotics and antimycobacterials), such as atovaquone, clarithromycin, erythromycin, fusidic acid (taken orally or administered by IV route), bedaquiline, rifabutin, delamanid and sulfamethoxazole/trimethoprim</p></li><li><p>medicines used to treat schizophrenia and abnormal thoughts or feelings, such as clozapine</p></li><li><p>medicines used to treat mental or mood disorders, such as haloperidol, risperidone and thioridazine</p></li><li><p>medicines used to treat high blood pressure in the blood vessels that supply the lungs, such as bosentan and riociguat</p></li><li><p>medicines used to treat high blood pressure (hypertension), such as amlodipine, diltiazem, felodipine, lercanidipine, nicardipine, nifedipine and verapamil</p></li><li><p>medicines used to treat heart and/or blood vessel problems, such as aliskiren, ticagrelor, cilostazol and clopidogrel</p></li><li><p>medicines used to treat heart conditions and correct irregular heartbeats, such as digoxin, amiodarone, flecainide and disopyramide</p></li><li><p>medicines to treat cystic fibrosis, such as ivacaftor, elexacaftor/tezacaftor/ivacaftor and tezacaftor/ivacaftor</p></li><li><p>medicines used to treat diabetes such as saxagliptin</p></li><li><p>medicines used to treat hepatitis C virus infection, such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir</p></li><li><p>medicines used to lower blood cholesterol, such as atorvastatin, fluvastatin, pravastatin and rosuvastatin</p></li><li><p>medicines used to treat migraine headaches, such as rimegepant</p></li><li><p>medicines used to treat urinary incontinence, such as darifenacin and solifenacine</p></li><li><p>medicines used to treat mental health problems, such as aripiprazole, brexpiprazole and cariprazine</p></li><li><p>medicines used to suppress your immune system, such as cyclosporine, everolimus, sirolimus and tacrolimus</p></li><li><p>medicines used to treat autoimmune disorders including rheumatoid arthritis, psoriatic arthritis or ulcerative colitis, such as tofacitinib and upadacitinib</p></li><li><p>medicines used to treat severe pain, such as morphine, fentanyl, oxycodone, methadone, buprenorphine, other morphine-like medicines, pethidine and piroxicam</p></li><li><p>medicines used as sedatives, hypnotics, and sleeping agent, such as alprazolam, buspirone and zolpidem</p></li><li><p>medicines used to treat attention deficit disorder or a sleep disorder called narcolepsy, such as amphetamines</p></li><li><p>steroids including corticosteroids used to treat inflammation, such as budesonide, dexamethasone, fluticasone, prednisolone and triamcinolone</p></li><li><p>medicines used to treat asthma and other lung-related problems such as chronic obstructive pulmonary disease [COPD], such as salmeterol and theophylline</p></li><li><p>medicines used to treat depression, such as amitriptyline, fluoxetine, imipramine, nortriptyline, paroxetine and sertraline</p></li><li><p>medicines used as thyroid replacement therapy, such as levothyroxine</p></li><li><p>medicine used to treat enlarged prostate, such as tamsulosin</p></li><li><p>any of the following other specific medicines:</p></li><li><p>oral or patch contraceptive containing ethinyl estradiol used to prevent pregnancy</p></li><li><p>midazolam administered by injection (used for sedation [an awake but very relaxed state of calm or drowsiness during a medical test or procedure] or anaesthesia)</p></li></ul><p>Many medicines interact with Paxlovid. Keep a list of your medicines to show your doctor(s) and pharmacist. Do not start taking a new medicine without telling your doctor(s). Your doctor(s) can tell you if it is safe to take Paxlovid with other medicines.</p><p>Pregnancy and breast-feeding<br/>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>There is not enough information to be sure that Paxlovid is safe for use in pregnancy. If you are pregnant, it is not recommended to use Paxlovid unless your clinical condition requires this treatment. It is recommended that you refrain from sexual activity or use contraception while taking Paxlovid and for 7 days after completing Paxlovid as a precaution. If you are taking hormonal contraception, as Paxlovid may reduce the effectiveness of this medicine, it is recommended that a condom or other non hormonal method of contraception is used. Your doctor will advise you on the duration of this required adjustment of your contraceptive measures.</p><p>There is no information on the use of Paxlovid in breast-feeding. You should not breast-feed your baby while taking Paxlovid and for 7 days after completing Paxlovid as a precaution.</p><p>Driving and using machines<br/>Paxlovid is expected to have no influence on the ability to drive and use machines.</p><p>Paxlovid contains lactose<br/>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>Paxlovid contains sodium Nirmatrelvir and ritonavir tablets each contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.</p></div>
</text>
</section>
<section>
<title value="3. How to take paxlovid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take paxlovid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Paxlovid consists of 2 medicines: nirmatrelvir and ritonavir. The recommended dose is 2 tablets of nirmatrelvir (pink tablet) with 1 tablet of ritonavir (white tablet) by mouth twice daily (in the morning and in the evening).</p><p>A course of treatment lasts 5 days. For each dose, take all 3 tablets together at the same time.</p><p>If you have kidney disease, please talk to your healthcare provider for an appropriate dose of Paxlovid.</p><p>Swallow the tablets whole. Do not chew, break or crush the tablets. Paxlovid can be taken with or without meals.</p><p>If you take more Paxlovid than you should If you take too much Paxlovid, call your healthcare provider or go to the nearest hospital emergency room right away.</p><p>If you forget to take Paxlovid If you miss a dose of Paxlovid within 8 hours of the time it is usually taken, take it as soon as you remember. If you miss a dose by more than 8 hours, skip the missed dose and take the next dose at your regular time. Do not take 2 doses of Paxlovid at the same time.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Paxlovid Even if you feel better, do not stop taking Paxlovid without talking to your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Common: may affect up to 1 in 10 people</p><ul><li>Diarrhoea</li><li>Vomiting</li><li>Nausea</li><li>Altered sense of taste (such as metallic, bitter taste)</li><li>Headache</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>Allergic reactions</li><li>High blood pressure</li><li>Abdominal pain</li><li>Muscle pain</li><li>Skin rash (also reported as part of allergic reaction)</li></ul><p>Rare: may affect up to 1 in 1000 people</p><ul><li>Severe allergic reaction known as anaphylaxis (such as swelling of tongue, mouth and face, trouble swallowing or breathing, throat tightness, or hoarseness)</li><li>Serious skin reactions known as toxic epidermal necrolysis and Stevens-Johnson syndrome<br/>(such as red and painful skin, blisters and peeling skin, blisters or sores in your mouth or lips)</li><li>Malaise</li><li>Itching (also reported as part of allergic reaction)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store paxlovid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store paxlovid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton or the blister after EXP . The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Paxlovid contains</p><ul><li>The active substances in this medicine are nirmatrelvir and ritonavir.</li><li>Each pink film-coated nirmatrelvir tablet contains 150 mg of nirmatrelvir.</li><li>Each white film-coated ritonavir tablet contains 100 mg of ritonavir.</li><li>The other ingredients in the nirmatrelvir tablet are microcrystalline cellulose, lactose monohydrate (see section 2, Paxlovid contains lactose ), croscarmellose sodium, colloidal silicon dioxide and sodium stearyl fumarate (see section 2, Paxlovid contains sodium ). The film-coating contains hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol and iron oxide red.</li><li>The other ingredients in the ritonavir tablet are copovidone, sorbitan laurate, colloidal anhydrous silica, anhydrous calcium hydrogen phosphate, sodium stearyl fumarate. The film-coating contains hypromellose, titanium dioxide, macrogol, hydroxypropyl cellulose, talc, colloidal anhydrous silica and polysorbate 80. What Paxlovid looks like and contents of the pack Paxlovid film-coated tablets are available in 5 daily-dose blister cards with a total of 30 tablets packaged in a carton.</li></ul><p>Each daily blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each) and indicates which tablets need to be taken in the morning and evening (sun and moon symbols).</p><p>Nirmatrelvir 150 mg film-coated tablets are pink, oval-shaped and debossed with PFE on one side and 3CL on the other side.</p><p>Ritonavir 100 mg film-coated tablets are white to off white, capsule shaped, and debossed with H on one side and R9 on the other side.</p><p>Marketing Authorisation Holder</p><p>Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Brussels Belgium</p><p>Manufacturer</p><p>Pfizer Manufacturing Deutschland GmbH<br/>Betriebsst tte Freiburg Mooswaldallee 1 79090 Freiburg Germany Pfizer Italia S.r.L. Localita Marino del Tronto 63100 Ascoli, Piceno<br/>Italy</p><p>Pfizer Ireland Pharmaceuticals<br/>Little Connell<br/>Newbridge Ireland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Luxembourg/Luxemburg<br/>Pfizer NV/SA T l/Tel: +32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4<br/>,</p><p>Te .: +359 2 970 4Magyarorsz g Pfizer Kft. Tel.: + 36 1 488 37 esk republika Pfizer, spol. s r.o. Tel: +420 283 004 Malta Vivian Corporation Ltd. Tel: +356 21344Danmark Pfizer ApS Tlf: +45 44 20 11 Nederland Pfizer bv Tel: +31 (0)800 63 34 Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51Norge Pfizer AS Tlf: +47 67 52 61 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7 sterreich Pfizer Corporation Austria Ges.m.b.H Tel: +43 (0)1 521 15-0</p><p>Pfizer A.E. : +30 210 6785Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 Espa a Pfizer, S.L. Tel: +34 91 490 99 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5France Pfizer T l: +33 (0)1 58 07 34 Rom nia Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 Hrvatska Pfizer Croatia d.o.o. Tel: +385 1 3908 Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) +44 (0)1304 616Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel: + 421 2 3355 5 sland Icepharma hf. S mi: +354 540 8Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 Italia Pfizer S.r.l. Tel: +39 06 33 18 Sverige Pfizer AB Tel: +46 (0)8 550 520<br/>Pfizer . . (Cyprus Branch) T : +357 22817United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0) 1304 616Latvija Pfizer Luxembourg SARL fili le Latvij<br/>Tel: + 371 670 35 This leaflet was last revised in</p><p>Scan the code with a mobile device to get the package leaflet in different languages.</p><p>URL: <a href="https://pfi.sr/c19oralrx">https://pfi.sr/c19oralrx</a></p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpc01e0605e2e3c43213448cfeba0686aa"/>
<resource>
<MedicinalProductDefinition>
<id value="mpc01e0605e2e3c43213448cfeba0686aa"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpc01e0605e2e3c43213448cfeba0686aa"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpc01e0605e2e3c43213448cfeba0686aa</b></p><a name="mpc01e0605e2e3c43213448cfeba0686aa"> </a><a name="hcmpc01e0605e2e3c43213448cfeba0686aa"> </a><a name="mpc01e0605e2e3c43213448cfeba0686aa-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1625/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Paxlovid 150 mg + 100 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1625/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Paxlovid 150 mg + 100 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
